Recommendations made by the PBAC – December 2019 intracycle meeting


13 February 2020 - The outcomes from the December 2019 PBAC intracycle meeting are now available.

The PBAC noted the outcomes from the November 2019 Medical Services Advisory Committee meeting for three medicines considered by PBAC in November 2019: brigatinib (Alunbrig), olaparib (Lynparza and ibrutinib (Imbruvica) and considered its impact on related PBS listings.

Read PBAC outcomes

Michael Wonder

Posted by:

Michael Wonder